Close
RNS Number : 2606G
ValiRx PLC
05 November 2018
 

 

 

 

VALIRX PLC

("ValiRx" or the "Company")

 

Re RECENT & FORTHCOMING SCIENTIFIC AND INVESTOR MEETINGS

London, UK., 05 November 2018: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company, provides the following update regarding recent and forthcoming scientific and investor meetings that management have already attended/presented at or are due to do so:

SCIENTIFIC MEETINGS

6th CPC Symposium on Peptide Therapeutics Conference, held in Hangzhou, China on 17- 19 October 2018

Dr George Morris, Chief Operating Officer at ValiRx PLC, was invited and recently presented a paper at the 6th CPC Symposium on Peptide Therapeutics in Hangzhou, China.  The Symposium traditionally brings together scientific leaders in peptide-based therapeutics from across the biopharmaceutical industries and academia and it provides a forum for scientific discussion on recent developments in the field of peptide therapeutics.

 

Dr Morris presented a paper entitled "A decapeptide (VAL201 - Pro-Pro-Pro-His-Pro-His-Ala-Arg-Ile-Lys) modulating hormone induced proliferative indications".  The paper examined preliminary results and data from the Phase I/II Clinical Study of the Company's therapeutic peptide (VAL201) and its targeting of the interaction between steroid hormone receptors and c-Src to inhibit cell proliferation activity, without blocking desirable receptor-dependent transcriptional activity and thereby eliminating most side effects associated with more general Src kinase inhibitors or with hormone deprivation therapies.

 

 

House of Lords' Life Sciences Industrial Strategy Reception on Monday 29th October 2018

 

Dr Satu Vainikka, CEO was invited by Viscount Matt Ridley DL on behalf of Professor Sir John Bell GBE to a Life Sciences reception last week at the House of Lords, which involved a group debate and feedback session.  The industry experts participating in the meeting discussed the issues relating to the UK's Life Sciences Industrial Strategy, both as they pertain currently and in the future. The debate was both wide ranging and informative.

 

 

5th Annual Clinical Operations in Oncology Europe Conference, held in Munich, Germany on 14-15 November 2018

 

Dr Morris will be attending and speaking next week at the Annual Clinical Operations in Oncology Europe Conference, in Munich, Germany.  His speech, entitled "The bird's eye view: Defining strategy to maintain vendor oversight in oncology clinical trials", will discuss various aspects pertaining to the running and management of the clinical trial process within GCP and regulatory guidelines.

 

INVESTOR MEETING

Shares and AJ Bell Investor Evening in Edinburgh, held at the Radisson Blu Hotel at 18:00 on Thursday, 22 November 2018

 

Dr Morris and colleagues, Tarquin Edwards, Head of Comms/IR and Kumar Nawani, Head of Operations, will attend the event, with Dr Morris making a presentation about the Company to existing and potential new investors.  He will discuss both the Company's current progress as far as its clinical and pre-clinical drug development programmes are concerned and will outline the company's business plans for the rest of 2018 and into the new year.

 

*** ENDS ***

 

For more information, please contact:

ValiRx plc

Tel: +44 (0) 20 3008 4416

www.valirx.com

Dr Satu Vainikka, Chief Executive

Tel: +44 (0) 20 3008 4416

Tarquin Edwards, Head of Communications.

Tel: +44 (0) 7879 458 364

tarquin.edwards@valirx.com

 

 

Notes for Editors

 

About ValiRx

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers.  It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

 

The Company's business model focuses on out-licensing therapeutic candidates early in the development process.  By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value.  The group is already in licensing discussions with major players in the oncology field.

 

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights.   They originate or derive from World class institutions, such as Cancer Research UK and Imperial College.

 

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy.  With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible.  New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

 

The Company listed on the AIM Market of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAVLLFBVFFEFBQ